Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7719587 | 0.86 | HRH1 (0.50) | MEN1KMT2ALOXL2HRH1CYP1A2 | |
| SCHEMBL7418781 | 0.83 | HRH1 (0.57) | MEN1KMT2ALOXL2HRH1HSD17B10 | |
| SCHEMBL8764230 | 0.82 | MEN1 (0.64) | MEN1KMT2ALOXL2CYP1A2CYP3A4 | |
| Water SCHEMBL31124596 | 0.79 | LOXL2 (0.65) | LOXL2HRH1CYP1A2CYP3A4CYP2D6 | |
| Water SCHEMBL31124597 | 0.79 | LOXL2 (0.65) | LOXL2HRH1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28826605 | 0.78 | KMT2A (0.46) | MEN1KMT2ALOXL2 | |
| SCHEMBL347893 | 0.76 | LOXL2 (0.50) | KMT2ALOXL2HRH1CYP1A2CYP3A4 | |
| SCHEMBL6319772 | 0.76 | LOXL2 (0.50) | LOXL2HRH1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL151822 | 0.76 | LOXL2 (0.68) | LOXL2HRH1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8763175 | 0.75 | MEN1 (0.56) | MEN1KMT2ALOXL2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3419963-B1 | USE OF BISPYRIDINES TO IMPROVE LABELING OF NUCLEOPHILES | AGILENT TECHNOLOGIES INC (US) | 2022-08-10 | — | — | EP | claimed |
| US-20210333269-A1 | Kits for Using Bispyridines to Improve Labeling of Nucleophiles | AGILENT TECHNOLOGIES, INC. (US) | 2021-10-28 | — | — | US | claimed |
| US-11092595-B2 | Use of bispyridines to improve labeling of nucleophiles | AGILENT TECHNOLOGIES, INC. (US) | 2021-08-17 | — | — | US | claimed |
| EP-2629777-A2 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-08-28 | — | — | EP | claimed |
| WO-2012054364-A2 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-04-26 | — | — | WO | claimed |
| US-20240327392-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVES AS MEDICAMENTS FOR TREATING AND/OR PREVENTING RS VIRUS INFECTIONS | ALBIUS SCIENCES ALPHA PRIVATE LIMITED (SG) | 2024-10-03 | — | — | US | disclosed |
| EP-4361148-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVE AS MEDICAL DRUG FOR TREATMENT AND/OR PREVENTION OF RS VIRUS INFECTIOUS DISEASE | Albius Sciences Alpha Private Limited (SG) | 2024-05-01 | — | — | EP | disclosed |
| CN-117730079-A | Heterocyclyl-substituted polyheterazoles derivatives as medicaments for the treatment and/or prophylaxis of RSV infections | 亚博思生物科技(第一)有限公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20220135547-A1 | HETEROCYCLIC LOW-MOLECULAR SAPP MIMETICS, A PHARMACEUTICAL COMPOSITION AND METHODS FOR PRODUCING AND USING SAME | NENAYDENOV VALENTIN G (RU) | 2022-05-05 | — | — | US | disclosed |
| EP-2626352-A1 | HETEROCYCLIC LOW-MOLECULAR SAPP MIMETICS, A PHARMACEUTICAL COMPOSITION AND METHODS FOR PRODUCING AND USING SAME | Obschestvo S Ogranichennoy Otvetstvennostju "Biopharm-Memorien" (RU) | 2013-08-14 | — | — | EP | disclosed |
| CN-101558040-B | Dihydropyridine derivatives useful as protein kinase inhibitors | BAYER SCHERING PHARMA AG | 2013-03-27 | — | — | CN | disclosed |
| WO-2012033435-A1 | METHOD, COMPOUND, PHARMACEUTICAL COMPOSITION AND DRUG FOR RESTORING MEMORY LOST IN NORMAL AND PATHOLOGICAL CONTEXTS | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "БИОФАРМ-МЕМОРЕЙН" (RU) | 2012-03-15 | — | — | WO | disclosed |
| WO-2007117180-A1 | AZAHETEROCYCLES, COMBINATORY LIBRARY, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITION AND METHODS FOR THE PRODUCTION THEREOF | 'CHEMICAL DIVERSITY RESEARCH INSTITUTE' LTD. (RU) | 2007-10-18 | — | — | WO | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-0372470-A2 | Novel alpha-cyano-beta-oxopropionamides | CIBA-GEIGY AG (CH) | 1990-06-13 | — | — | EP | disclosed |
| US-4605744-A | ANTIBIOTICS | HOFFMANN-LA ROCHE INC. (US) | 1986-08-12 | — | — | US | disclosed |
| US-4537969-A | AZOLE-SUBSTITUTED SATURATED HETEROCYCLIC CARBOXALDEHYDE ACETALS;INTERMEDIATES FOR 6-AMIDINOPENICILLINS | HOFFMANN-LA ROCHE INC. (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0148283-A1 | Novel penicillanic acid derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1985-07-17 | — | — | EP | disclosed |
| US-4431653-A | ANTIBIOTICS; BACTERICIDES; SSYNERGISTIC WITH AMINO ACID DERIVATIVE | HOFFMANN-LA ROCHE INC. (US) | 1984-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11092595-B2 | Use of bispyridines to improve labeling of nucleophiles | PTMS, BTD, DPYD | MEN1 2643/4885KMT2A 1691/4885LOXL2 2305/4885 |
| US-20240327392-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVES AS MEDICAMENTS FOR TREATING AND/OR PREVENTING RS VIRUS INFECTIONS | RSU1, TSLP, HAVCR2 | MEN1 1938/4885KMT2A 2365/4885LOXL2 1388/4885 |
| US-20210333269-A1 | Kits for Using Bispyridines to Improve Labeling of Nucleophiles | DPYD, UNG, BTD | MEN1 2506/4885KMT2A 1503/4885LOXL2 2603/4885 |
| US-20220135547-A1 | HETEROCYCLIC LOW-MOLECULAR SAPP MIMETICS, A PHARMACEUTICAL COMPOSITION AND METHODS FOR PRODUCING AND USING SAME | APP, IAPP, BDNF | MEN1 2764/4885KMT2A 4703/4885LOXL2 4279/4885 |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | MEN1 203/4885KMT2A 3139/4885LOXL2 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.